Skip to main content
Clinical Trials/NCT02031419
NCT02031419
Terminated
Phase 1

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Celgene16 sites in 4 countries174 target enrollmentDecember 18, 2013

Overview

Phase
Phase 1
Intervention
CC-122
Conditions
Lymphoma, Large B-Cell, Diffuse
Sponsor
Celgene
Enrollment
174
Locations
16
Primary Endpoint
Safety
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Detailed Description

Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122, CC-223 and CC-292 administered orally as doublets with or without rituximab, in participants with relapsed/refractory DLBCL who have failed standard therapy. In expansion phase, selected combination will be administered to lenalidomide naïve FL participants and lenalidomide exposed FL participants in addition to relapsed/refractory DLBCL participants.

Registry
clinicaltrials.gov
Start Date
December 18, 2013
End Date
December 12, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Celgene
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men and women, 18 years or older, with histologically or cytologically-confirmed either:
  • Chemo-refractory DLBCL (including transformed low grade lymphoma)
  • Lenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) following at least one prior standard systemic treatment regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least one prior line of salvage therapy with no prior exposure to lenalidomide, or double-refractory FL participants with no prior exposure to lenalidomide (FL-1 cohort)
  • Lenalidomide exposed: relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) previously treated with at least two cycles of lenalidomide-containing regimen (FL-2 cohort), either as a single agent or in combination
  • At least one site of measurable disease
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or
  • Participants must have the following laboratory values:
  • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L (with bone marrow involvement with DLBCL)
  • Hemoglobin (Hgb) ≥ 8 g/dL.
  • Potassium within normal limits

Exclusion Criteria

  • Symptomatic central nervous system involvement.
  • Known symptomatic acute or chronic pancreatitis.
  • Persistent diarrhea or malabsorption despite medical management.
  • Peripheral neuropathy ≥ grade 2
  • Impaired cardiac function or clinically significant cardiac diseases
  • Participants with diabetes on active treatment (for participants treated on CC-223 containing arms only)
  • Prior autologous stem cell transplant (ASCT) ≤ 3 months before first dose.
  • Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.
  • Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting study drugs, whichever is shorter.
  • Participants who have undergone major surgery ≤ 2 weeks prior to starting study drugs.

Arms & Interventions

CC-122 + CC-223 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-122

CC-122 + CC-223 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-223

CC-122 + CC-223 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: Rituximab

CC-122 + CC-292 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-122

CC-122 + CC-292 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-292

CC-122 + CC-292 +/- rituximab

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days

Intervention: Rituximab

CC-292 + CC-223 +/- rituximab

CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-223

CC-292 + CC-223 +/- rituximab

CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: CC-292

CC-292 + CC-223 +/- rituximab

CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Intervention: Rituximab

CC-122 + rituximab

CC-122 administered orally once daily in combination with Rituximab.

Intervention: CC-122

CC-122 + rituximab

CC-122 administered orally once daily in combination with Rituximab.

Intervention: Rituximab

Outcomes

Primary Outcomes

Safety

Time Frame: From the time of informed consent, throughout dosing period and for 28 days after the last dose of study drug.

To determine safety profiles and dose-limiting toxicities of study drug combinations using NCI CTCAE v4.

Secondary Outcomes

  • Pharmacokinetics - CC-223 and CC-292 interaction(Day 1, Day 15)
  • Efficacy(Every 2-3 months until proof of tumor progression)

Study Sites (16)

Loading locations...

Similar Trials